Cross-Market Price Comparison
| Other Listed Market | Shanghai (SSE) — 荣昌生物 |
|---|---|
| Other Market Stock Code | 688331 |
| H-Share Offer Price | HK$ 52.10 |
| Other Market Price | Loading... |
| Reference Exchange Rate | Loading... |
| H-Share Offer Price Premium/Discount vs Other Market | Loading... |
Company Overview
| Stock Name | Remegen |
|---|---|
| Stock Code | 09995 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 一家正在進入商業化階段的生物製藥公司,致力於發現、開發和商業化創新的、有特色的生物藥,用於治療中國乃至全球多種醫療需求未被滿足的自身免疫、腫瘤科和眼科疾病。 |
| Listing Date | 2020-11-09 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國山東省自由貿易試驗區煙台片區煙台開發區北京中路58號 |
| Business Address (Hong Kong) | 香港灣仔皇后大道東248號陽光中心40樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.remegen.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | 18A生物科技 |
|---|---|
| Offer Price | HK$ 52.10 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 500 shares |
| Entry Threshold | HK$ 26,050 |
| Par Value | RMB 1.0 / shares |
| Offer Period | 2020-10-28 to 2020-11-02 |
| Global Offering Shares | 76,537,000 shares |
| HK Public Offer Shares (Initial) | 7,654,000 shares (10.0%) |
| Public Offer Lots (Initial) | 15,308lots (Pool A7,654lots,Pool B7,654lots) |
| International Placing Shares (Initial) | 68,883,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 478,356,202 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 44.2% |
| Clawback Tiers | To be extracted |
| Reallocation Option | No |
| Total Global Offering Size | HK$ 3,987,577,700 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 500 | HK$ 26,050 |
| 2 lots | 1,000 | HK$ 52,100 |
| 3 lots | 1,500 | HK$ 78,150 |
| 4 lots | 2,000 | HK$ 104,200 |
| 5 lots | 2,500 | HK$ 130,250 |
| 6 lots | 3,000 | HK$ 156,300 |
| 7 lots | 3,500 | HK$ 182,350 |
| 8 lots | 4,000 | HK$ 208,400 |
| 9 lots | 4,500 | HK$ 234,450 |
| 10 lots | 5,000 | HK$ 260,500 |
| 12 lots | 6,000 | HK$ 312,600 |
| 14 lots | 7,000 | HK$ 364,700 |
| 16 lots | 8,000 | HK$ 416,800 |
| 18 lots | 9,000 | HK$ 468,900 |
| 20 lots | 10,000 | HK$ 521,000 |
| 30 lots | 15,000 | HK$ 781,500 |
| 40 lots | 20,000 | HK$ 1,042,000 |
| 50 lots | 25,000 | HK$ 1,302,500 |
| 60 lots | 30,000 | HK$ 1,563,000 |
| 70 lots | 35,000 | HK$ 1,823,500 |
| 80 lots | 40,000 | HK$ 2,084,000 |
| 90 lots | 45,000 | HK$ 2,344,500 |
| 100 lots | 50,000 | HK$ 2,605,000 |
| 120 lots | 60,000 | HK$ 3,126,000 |
| 140 lots | 70,000 | HK$ 3,647,000 |
| 160 lots | 80,000 | HK$ 4,168,000 |
| 180 lots | 90,000 | HK$ 4,689,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 200 lots | 100,000 | HK$ 5,210,000 |
| 400 lots | 200,000 | HK$ 10,420,000 |
| 600 lots | 300,000 | HK$ 15,630,000 |
| 800 lots | 400,000 | HK$ 20,840,000 |
| 1,000 lots | 500,000 | HK$ 26,050,000 |
| 1,200 lots | 600,000 | HK$ 31,260,000 |
| 1,400 lots | 700,000 | HK$ 36,470,000 |
| 1,600 lots | 800,000 | HK$ 41,680,000 |
| 1,800 lots | 900,000 | HK$ 46,890,000 |
| 2,000 lots | 1,000,000 | HK$ 52,100,000 |
| 2,500 lots | 1,250,000 | HK$ 65,125,000 |
| 3,000 lots | 1,500,000 | HK$ 78,150,000 |
| 3,500 lots | 1,750,000 | HK$ 91,175,000 |
| 4,000 lots | 2,000,000 | HK$ 104,200,000 |
| 4,500 lots | 2,250,000 | HK$ 117,225,000 |
| 5,500 lots | 2,750,000 | HK$ 143,275,000 |
| 6,000 lots | 3,000,000 | HK$ 156,300,000 |
| 6,500 lots | 3,250,000 | HK$ 169,325,000 |
| 7,654 lots | 3,827,000 | HK$ 199,386,700 |
Stock Connect Inclusion Analysis
| HK Market Cap | HK$ 16.73B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 24,922,358,124 |
|---|---|
| H-Share Market Cap (at Offer Price) | HK$ 5,567,842,441 |
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不適用(公司處於虧損狀態) |
| Profit/Loss Status | 虧損人民幣430.3百萬元 |
| Period-End Cash Balance | 人民幣34.5百萬元 |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2018 | 2019 |
|---|---|---|
| Revenue | 11,321 | 0 |
| Cost of sales | -8,932 | 0 |
| Gross profit | 2,389 | 0 |
| Other income and gains, net | 15,377 | 38,481 |
| Selling and distribution expenses | 0 | -621 |
| Administrative expenses | -29,125 | -68,434 |
| Operating profit | -229,893 | -386,491 |
| Net finance costs | -40,055 | -43,789 |
| Profit before tax | -269,948 | -430,280 |
| Income tax expense | 0 | 0 |
| Profit for the year | -269,948 | -430,280 |
| Profit attributable to owners | -269,948 | -430,280 |
Balance Sheet
| Item | 2018 | 2019 | 2020-06 |
|---|---|---|---|
| Cash and cash equivalents | 5,069 | 34,545 | |
| Trade and bills receivables | 10,969 | 1,058 | |
| Inventories | 29,671 | 31,247 | |
| Total current assets | 64,884 | 137,574 | |
| Total assets | 531,092 | 689,311 | |
| Total current liabilities | 996,939 | 856,953 | |
| Total liabilities | 1,029,270 | 921,280 | |
| Total equity | -498,178 | -231,969 | |
| Equity attributable to owners | -498,178 | -231,969 | |
| Interest-bearing borrowings | 0 | 60,000 | 0 |
Cash Flow Statement
| Item | 2018 | 2019-06 | 2019 | 2020-06 |
|---|---|---|---|---|
| Net cash from operating activities | -128,028 | -282,746 | ||
| Net cash from investing activities | -77,172 | -95,100 | ||
| Depreciation of PP&E | 20,542 | 18,920 | 40,203 | 23,458 |
| Depreciation of right-of-use assets | 803 | 815 | 1,769 | 6,766 |
| Amortisation of intangible assets | 1,294 | 400 | 800 | 400 |
| Purchase of PP&E | -83,722 | -38,261 | -65,209 | -181,436 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 69.8 |
|---|---|
| First Day Open | HK$ 60.6 |
| First Day Change | 33.97% |
| First Day Volume | 35719000.0 |
| First Day Turnover | 2297640000.0 |
| Use of Proceeds | 1、約50.0%,或243.65百萬美元(1,888.29百萬港元),將主要用于候選藥物的臨床開發及商業化;
2、約25.0%,或121.82百萬美元(944.14百萬港元)將用于撥付建設新生產設施以擴大商業生產產能;
3、約15.0%,或73.09百萬美元(566.49百萬港元)將用于償還榮昌制藥借款;
4、約10.0%,或48.73百萬美元(377.66百萬港元)將用作一般企業及營運資金用途。 |
Underwriting Syndicate
Joint Sponsors (3)
Overall Coordinators (4)
Joint Bookrunners (8)
Morgan Stanley Asia Limited CE AAD291
HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321
UBS Securities Hong Kong Limited CE BIN466
中银国际亚洲有限公司 CE AET863
交银国际证券有限公司 CE APJ121
海通国际证券有限公司 CE AAF806
ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855
Joint Lead Managers (8)
Morgan Stanley Asia Limited CE AAD291
HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321
UBS Securities Hong Kong Limited CE BIN466
中银国际亚洲有限公司 CE AET863
交银国际证券有限公司 CE APJ121
海通国际证券有限公司 CE AAF806
ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | BlackRock Funds | 154,997,500 HKD | — | 3.89% | — | 6 months | 2021-05-09 |
| 2 | Cherry Tomatoes International Limited | 38,736,350 HKD | — | 0.97% | — | 6 months | 2021-05-09 |
| 3 | Cormorant Asset Management, LP | 77,498,750 HKD | — | 1.94% | — | 6 months | 2021-05-09 |
| 4 | CPE Greater China Enterprises Growth Fund | 46,499,250 HKD | — | 1.17% | — | 6 months | 2021-05-09 |
| 5 | Fidelity International | 294,495,250 HKD | — | 7.39% | — | 6 months | 2021-05-09 |
| 6 | GIC Private Limited | 77,498,750 HKD | — | 1.94% | — | 6 months | 2021-05-09 |
| 7 | Hillhouse Funds | 77,498,750 HKD | — | 1.94% | — | 6 months | 2021-05-09 |
| 8 | Hudson Bay Master Fund LTD | 77,498,750 HKD | — | 1.94% | — | 6 months | 2021-05-09 |
| 9 | Janchor Partners Pan-Asian Master Fund | 92,998,500 HKD | — | 2.33% | — | 6 months | 2021-05-09 |
| 10 | Lake Bleu Prime Healthcare Master Fund Limited | 154,997,500 HKD | — | 3.89% | — | 6 months | 2021-05-09 |
| 11 | LAV Amber Limited | 154,997,500 HKD | — | 3.89% | — | 6 months | 2021-05-09 |
| 12 | Matthews Asia Funds | 77,498,750 HKD | — | 1.94% | — | 6 months | 2021-05-09 |
| 13 | Octagon Investments Master Fund LP | 61,999,000 HKD | — | 1.55% | — | 6 months | 2021-05-09 |
| 14 | OrbiMed Funds | 116,235,100 HKD | — | 2.92% | — | 6 months | 2021-05-09 |
| 15 | Vivo Funds | 77,498,750 HKD | — | 1.94% | — | 6 months | 2021-05-09 |
| 16 | 加皇环球资产管理(亚洲)有限公司 | 54,236,100 HKD | — | 1.36% | — | 6 months | 2021-05-09 |
| 17 | 新华资本管理有限公司 | 38,736,350 HKD | — | 0.97% | — | 6 months | 2021-05-09 |
| 18 | 易方达基金管理有限公司 | 42,617,800 HKD | — | 1.07% | — | 6 months | 2021-05-09 |
| 19 | 中国生物制药有限公司 | 46,499,250 HKD | — | 1.17% | — | 6 months | 2021-05-09 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 王威東 | — |
| Company Secretary | 李嘉、譚栢如 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 王威東先生、房健民博士等一致行動人士為控股股東,合共持有約47.32%股份;其他主要股東包括國投創業、PAG、深創投等。 |
|---|




